Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857617 · ClinicalTrials.gov registry record · Phase 1
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity
A Phase 1 study, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT06857617 is a Phase 1 study that has completed, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants.
The verdict
NCT06857617, a Phase 1 study, has completed, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET097 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET097 or placebo. In Part C, participants will receive once-weekly doses of MET097 or placebo for 12 weeks, followed by a single dose at 2X or 4X to explore the potential for once-monthly dosing.
Interventions
- BIOLOGICAL (Part C) MET097
- BIOLOGICAL (Part C) Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06857617
The ClinicalTrials.gov registry entry for NCT06857617 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metsera, a wholly owned subsidiary of Pfizer, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which (Part C) MET097 is the first listed.
NCT06857617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06857617 about?
NCT06857617 is a clinical study titled "This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity". The goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity. The trial will be conducted in three parts. Part A consists of single ascending do...
What is the current status of trial NCT06857617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2024-04-01. Estimated completion is 2025-03-15.
What interventions are being tested in trial NCT06857617?
The interventions under investigation include: (Part C) MET097 (BIOLOGICAL), (Part C) Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06857617?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.